Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

Published:2021-06-28 Issue:1 Volume:74 Page:483-490
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Pinato David J.¹,Fessas Petros¹,Sapisochin Gonzalo²,Marron Thomas U.³

Affiliation:

1. Department of Surgery & Cancer Imperial College LondonHammersmith Hospital London United Kingdom

2. Multi‐Organ Transplant and HPB Surgical Oncology, Division of General Surgery, Toronto General Hospital, Department of Surgery University of Toronto Toronto Canada

3. Department of Medicine Division of Hematology/Oncology Tisch Cancer InstituteMount Sinai Hospital New York NY

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31697

Reference44 articles.

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

2. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

4. Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

5. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study;Journal of Hepatology;2024-09

2. Injectable thermosensitive microsphere-hydrogel composite system: combined therapy of hepatocellular carcinoma by remodeling tumor immune microenvironment;Science China Materials;2024-08-26

3. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance;eLife;2024-08-15

4. Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma;iScience;2024-06

5. Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy;Frontiers in Oncology;2024-05-10